AUERBACH ALAN H 4

What Happened

• Alan H. Auerbach, reported as a 10% owner (and noted as an employee in the filing), was granted equity awards by PUMA BIOTECHNOLOGY, INC. on Feb 18, 2026.
• The filing shows 159,778 Restricted Stock Units (RSUs) and 227,474 derivative awards (options) granted, each recorded at $0.00 purchase price (total reported cash consideration $0.00). These are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: February 18, 2026; Filing date (accession): Feb 20, 2026 (timely — within the typical 2-business-day Form 4 window).
• Reported prices: $0.00 for both grants (standard for awarded RSUs/options).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — RSUs vest in four equal installments: July 1, 2026; Jan 1, 2027; July 1, 2027; Jan 1, 2028 (subject to continued employment and certain acceleration events). F2 — Options follow the same four-quarter vesting schedule and are exercisable upon vesting (subject to acceleration in certain events).
• Transaction code: A = Award/Grant; the derivative line indicates option-type awards (not an immediate exercise or sale).

Context

• These grants are non-cash compensation and reflect future potential ownership if vesting and (for options) exercise conditions are met; they do not indicate an immediate purchase or sale of shares.
• As a reported 10% owner and employee, Auerbach’s awards are part of insider compensation and should be viewed differently than open-market insider purchases (which some investors regard as a stronger bullish signal).